<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid Antibodies</z:hpo> has been associated with severe maternal and fetal sequels, like <z:e sem="disease" ids="C0000809" disease_type="Disease or Syndrome" abbrv="">recurrent miscarriage</z:e>, <z:hpo ids='HP_0011420'>death</z:hpo>, <z:hpo ids='HP_0001511'>intrauterine growth retardation</z:hpo>, pregnancy-induced <z:e sem="disease" ids="C0020538" disease_type="Disease or Syndrome" abbrv="HTN">hypertensive disease</z:e>, thromboembolic phenomena and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Pathogenesis has been explained reporting that IgG from women with <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> increases placenta <z:chebi fb="0" ids="26995">thromboxane</z:chebi> production without affecting prostacyclin production, which conducts to <z:mp ids='MP_0005048'>thrombosis</z:mp> of placenta uterus junction </plain></SENT>
<SENT sid="2" pm="."><plain>In 1982, it was suggested for the first time low doses of aspirin and <z:chebi fb="0" ids="8382">prednisone</z:chebi> for treatment of recurrent fetal <z:hpo ids='HP_0011420'>death</z:hpo> associated to this syndrome, <z:chebi fb="5" ids="28304">heparin</z:chebi> therapy was reported in 1984, recommended a doses of 15,000 U/day during first pregnancy trimester and 20,000 U/day posteriorly </plain></SENT>
<SENT sid="3" pm="."><plain>The objective of this report, is the description a clinic case of a patient with recurrent fetal <z:hpo ids='HP_0011420'>death</z:hpo> and <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> syndrome, discussing a prenatal and obstetric treatment model, including diagnosis and final therapeutic, which includes the participation of some other specialists, the national experience in diagnosis and treatment is initial, and also because it has been reported a rate of fetal <z:hpo ids='HP_0011420'>death</z:hpo> in those patient with no treatment, almost of 90% </plain></SENT>
<SENT sid="4" pm="."><plain>The importance of identify this syndrome is not based on its prevalence but on its maternal complications and that it is a cause of fetal <z:hpo ids='HP_0011420'>death</z:hpo> potentially treatable </plain></SENT>
</text></document>